Sustained Disease Control Seen With Long-Term Belimumab in SLE
Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.
ACR/ARHP 2016 Annual Meeting
Smoking Leads to Worse RA Flare and Remission Patterns
Tobacco smoking adversely impacts rheumatoid arthritis (RA) flare and remission rates, according to findings from a long-term retrospective, population-based cohort study, presented at the 2016 ACR/ARHP Annual Meeting.
Temporary MTX Discontinuation Ups Flu Vaccine Efficacy in RA
Temporarily discontinuing methotrexate (MTX) treatment can improve seasonal influenza vaccination immunogenicity among patients with rheumatoid arthritis (RA), according to a single center, randomized, single-blind, open-label prospective study (NCT02748785) presented at the 2016 ACR/ARHP Annual Meeting.
Infliximab vs. Biosimilar: Discontinuation Rates Compared
Medical records of 1,044 patients with RA, new to starting treatment with Remicade or CT-P13, were analyzed in the study.
Anti-TNF Agents Go Head-to-Head in RA Superiority Study
The trial compares short- and long-term outcomes of Cimzia and Humira in RA
Tofacitinib Effective in PsA Patients With Prior Inadequate Response
Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study
Large RA Survey Finds 61% of Patients Uncomfortable Voicing Concerns
Results from a global survey given to patients and physicians showed that good communication is “critical to achieve optimal care”.
Sarilumab Offers Durable Clinical Responses for RA After 3 Years
The IL-6Rα -targeting human mAb sarilumab offers durable responses against rheumatoid arthritis (RA), according to an analysis of 3-year clinical and radiographic outcomes and safety for patients from the MOBILITY open-label extension study.
Sarilumab Efficacy, Safety Comparable Among RA Patient Subgroups
The IL-6Rα -targeting human mAb sarilumab exhibits comparable efficacy and safety for different patient subgroups in rheumatoid arthritis.
Long-Term Adalimumab Reduces Uveitis and Corticosteroid Dose
Adalimumab (Humira) helps treat non-infectious intermediate, posterior, or panuveitis (NIPPU), according to findings from an open-label clinical trial extension, VISUAL-III
Want to read more?
Please login or register first to view this content.
